









Markets
/
Stocks
/
nasdaq-amrx
/

Amneal Pharmaceuticals Inc

AMRX

14.520USD

-0.250-1.69%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.56BMarket Cap

814.81P/E TTM



Amneal Pharmaceuticals Inc

14.520

-0.250-1.69%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Amneal Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Amneal Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amneal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

25 / 159

Overall Ranking

73 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Amneal Pharmaceuticals Inc Highlights

StrengthsRisks

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.29% year-on-year.

Overvalued

The company’s latest PE is 814.81, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 154.72M shares, increasing 0.04% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.61M shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.500

Target Price

-1.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Amneal Pharmaceuticals Inc is 8.57, ranking 57 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 784.51M, representing a year-over-year increase of 11.68%, while its net profit experienced a year-over-year increase of 1618.59%.

Score

Industry at a Glance

Previous score

8.57

Change



Financials

5.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.59

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Amneal Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Amneal Pharmaceuticals Inc is 8.19, ranking 25 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 814.81, which is 24.62% below the recent high of 1015.40 and 149.94% above the recent low of -406.91.

Score

Industry at a Glance

Previous score

8.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 25/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Amneal Pharmaceuticals Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 13.50, with a high of 15.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.500

Target Price

-1.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Amneal Pharmaceuticals Inc

AMRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Amneal Pharmaceuticals Inc is 9.40, ranking 26 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 15.46 and the support level at 13.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.62

Change

-0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.131

Buy

RSI(14)

66.899

Neutral

STOCH(KDJ)(9,3,3)

70.032

Neutral

ATR(14)

0.493

High Vlolatility

CCI(14)

118.908

Buy

Williams %R

25.000

Buy

TRIX(12,20)

0.474

Sell

StochRSI(14)

3.256

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

14.432

Buy

MA10

14.130

Buy

MA20

13.703

Buy

MA50

12.991

Buy

MA100

11.789

Buy

MA200

10.013

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Amneal Pharmaceuticals Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 55.65%, representing a quarter-over-quarter decrease of 1.69%. The largest institutional shareholder is The Vanguard, holding a total of 17.85M shares, representing 5.68% of shares outstanding, with 13.27% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Patel (Tushar Bhikhubhai)

48.58M

-9.33%

Patel (Chintu)

25.62M

Patel (Dipan)

23.83M

Patel (Chirag K)

22.13M

Akram (Mahesh)

20.56M

-23.45%

The Vanguard Group, Inc.

Star Investors

17.90M

+2.31%

Rubric Capital Management LP

12.33M

+5.33%

TPG Capital, L.P.

12.33M

BlackRock Institutional Trust Company, N.A.

11.34M

+6.55%

Citadel Advisors LLC

5.73M

+1.86%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Amneal Pharmaceuticals Inc is 8.42, ranking 26 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Amneal Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.